Gendius launches crowdfunding pre-registration

Gendius has launched pre-registration for early access to an upcoming crowdfunding campaign via CrowdCube. Having already reached 75% of its £400k target, it is looking for those with a passion for the mHealth/diabetes to invest in its innovative intellin® platform.

intellin® uses artificial intelligence to calculate an individuals risk of developing complications from their diabetes and then tells them how to manage these.

With an ambitious growth plan, Gendius will look to drive the uptake in the EU and prepare for launches in the US, Middle East and South East Asia. It will use the funds raised to further improve the app functionality and user experience, develop their Artificial Intelligence algorithms as well as gaining the NHS and App store users as paying customers.

Progress

2017 – won £500K Innovate award for a clinical trial at Salford Royal NHS Foundation Trust
2017 – won £500K Venture Capital backing from Catapult Ventures
2017 – won £60K SBRI (small business research initiative) award for research into gestational diabetes
2018 – won £25K Momentum award from Health Innovation Manchester to complete UX/UI research
2019 – passed ISO27001
2019 – Our first NHS pilot
2019 – Over 3000 downloads in UK & EU
2019 – invited to HIMSS Health 2.0 conference for live demo of the app & 1 of 8 companies invited to pitch to investors
2019 – Bronze award from ORCHA (an independent review of intellin®)